Generic API

Generic API

Generic API

Olon is a leading international Generic Active Pharmaceutical Ingredients (API) supplier. We manufacture API via chemical as well as biological synthesis, relying on extended internal technical expertise while meeting the highest standards of quality and reliability, being competitive and cost-effective.

With a portfolio of 300 Generic APIs, we offer one of the most extensive track records in the industry, and we manage more than 450 Drug Master Files WW. Our portfolio embraces all the major therapeutic areas including oncology, CNS, infectious disease, immunology, dermatology, cardiovascular and many others.

Being an early adopter of the most advanced technology and processes, and handling the broadest range of analytical capabilities, we represent a partner enhancing competitiveness and time to market.

We have diversified and backed investments across several lines and multiple facilities to be able to manage various high-containment molecules at different scales and guarantee flexibility on a significant scale.

Our comprehensive analytical testing services are carried out fully in house; this translates to significant time and cost savings for our clients. Our clients can also rely on one of the widest ranges of leading-edge technologies, chemistry, and biotechnology expertise.
We represent an agile and versatile API provider able to meet the needs of the most demanding clients, both of generic and innovative pharma industry.

We customize our API from a chemical and physical viewpoint to match the specific and stringent project requirements of our customers; furthermore, our strong quality and regulatory expertise allow us to manage at best the approvals from the most demanding local authorities.

We are longstanding leader of the retinoid market, thanks to a product portfolio that includes all the main active ingredients in this class, as Tretinoin, Etretinate, Fenretinide, Isotretinoin, Alitretinoin, Tazarotene, Acitretin, and Trifarotene.
Olon also recorded a significant strengthening of its active ingredients for respiratory use which has been driven by the focus on innovative product applications to niche therapeutic areas with great unmet needs, and on developing specific physical properties of molecules for the administration via innovative inhalers.
In continuity with the latest developments, we have developed several new ‘NIBs’ with proprietary technology and patent filings.We are licensed to import narcotic raw materials on a commercial scale and routinely manufacture and distribute controlled substances such as psychotropics and intermediate lysergic acid throughout the world. Schedule III and IV APIs are currently licensed: Diethylpropion HCl, Phendimetrazine Tartrate, Phentermine HCl, Benzphetamine HCl.
Looking at the next steps, we will focus on ADCs as the next opportunity for the world of generic drugs, significantly raising the complexity and expertise levels.Our strategy, which underpins the development of our generic pipeline, contributes substantially to the sustainability of the healthcare system as it can ensure the launch of essential therapies on the generic market and their marketing at an affordable price.

Our API Portofolio

With one of the broadest track records of the industry, Olon portfolio is highly differentiated and includes, among others, products produced by microbial fermentation, HPAPI, controlled substances, retinoic API. Consult our APIs portfolio.
Schedule III and IV APIS are currently licensed: Diethylpropion HCI, Phendimetrazine Tartrate, Phentermine HCI, Benzphetamine HCI.

CAS nr: 522-51-0
Infectious Disease (Women Health)